Products and services

Contact and locations

Activery The amorphization specialist

Activery The amorphization specialist

Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics

Service analyse DSC

SERVICE ANALYSE DSC ET TGA Activery offre aussi le service d analyse thermique (analyse DSC et TGA) en externalisation. Nous effectuons l analyse thermique pour différents produits chimies, polymères, cosmétiques et , spécialement, pour produits pharmaceutiques come des principes actives ou for...

Creating new paths to differentiated medicines

Creating new paths to differentiated medicines

In Activery we believe that solid state modifications may lead to a critical changes in your active pharmaceutical, thus to a differentiated drug or to a brand new innovative medicine  

Activery, the solid state specialist

Activery, the solid state specialist

Activery possess unrivalled specialist expertise about different crystallization techniques and expert knowledge in the field of solid state modulation.  

Particles and nanoparticles for special uses

Particles and nanoparticles for special uses

In Activery, we design and produce particles for special uses where size matters such as nanoparticles for cancer treatment. Through our technology you would enable new administration routes or renewed performance of your drug formulation.  

•The global pharmaceutical market is forecast to grow to US$897 billion in 2011, an equivalent CAGR of 6.9% over the next five years PDF Print E-mail


Headline findings




•The global pharmaceutical market is forecast to grow to US$897 billion in 2011, an equivalent CAGR of 6.9% over the next five years.
•Strong growth in the 10 European markets that joined the European Union in 2004 will help to boost European sales over the next five years.
•In 2006 the leading therapy areas by sales were cardiovascular with 14.2% share and CNS with 14.1%.
•Continued double-digit market growth in China will make it the seventh biggest drug market by sales in 2010.
•The top 100 blockbuster drugs generated sales of US$232.2 billion accounting for 36% of the total pharma market.
•Total pharmaceutical sales from the top 10 companies accounted for more than 40% of the total market.
Key features of the report

•Comprehensive market trends for key countries, regions, therapy areas, products and companies.
•Country profiles for leading pharma markets with market segment trends and 5 year forecasts.
•Therapy area profiles for leading therapeutic classes and key products and 2010 sales forecasts.
•Detailed profiles of 10 leading pharmaceutical products in 2006, including five year future sales forecasts.
•Detailed profiles of 10 leading pharmaceutical companies in 2006, including 2011 sales forecasts.(AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson and Johnson, Merck & Co, Novartis, Pfizer, Roche, Sanofi-Aventis Wyeth)
•173 pages long, with 87 figures and 67 tables to illustrate the market trends.
Use this report to:

1. Benchmark your portfolio against key market trends and forecasts in order to plan better for success.

2. Identify key areas of pharmaceutical market growth and key opportunities for delivering successful sales growth over the next five years.

3. Support internal planning and decision-making with an external perspective founded on detailed analysis and transparent market forecasts.

Report coverage


The report methodology provides a detailed but transparent analysis of key pharmaceutical market trends, including key markets, therapy areas, products and companies. Historical trends are formed over a three-year time horizon and future forecasts are made using a five-year future time period. Thus, the data and analysis relate to the nine-year time horizon from 2003 to 2011.

All data used in outlining historical trends is clearly sourced within the report and any data limitations or additional assumptions are explicitly detailed within the text of the report. Future market forecasts are projected based on both historical trends and future expectations over market conditions and events. The assumptions used to form the basis of key market forecasts are outlined in detail within the text of the report.


Table of Contents
[ show / hide ]

Executive Summary
Introduction
Key global markets
Key therapeutic markets
Key products
Key companies
Key trends and opportunities

Chapter 1 Introduction
Global pharmaceutical market
Report overview


Methodology
Sources
Structure

Chapter 2 Key global markets
Key pharmaceutical markets
US pharmaceutical market

US purchasing channels
US retail drug market
US therapy areas
US market leaders
European pharmaceutical market

European retail drug market
European therapy areas

Japanese pharmaceutical market

Japanese therapy areas


Chapter 3 Key therapeutic markets
Key therapy areas

Retail drug therapy areas

Cardiovascular therapy area

Cardiovascular markets
Cardiovascular blockbusters

Central nervous system therapy area

Central nervous system markets
Central nervous system blockbusters
Alimentary/ metabolism therapy area

Alimentary/ metabolism markets
Alimentary/ metabolism blockbusters
Respiratory therapy area

Respiratory markets
Respiratory blockbusters
Anti-infectives therapy area

Anti-infectives markets
Anti-infectives blockbusters
Musculo-skeletal therapy area

Musculo-skeletal markets
Musculo-skeletal blockbusters
Cytostatics therapy area

Cytostatics markets
Cytostatics blockbusters

Chapter 4 Key products
Leading products

Lipitor (atorvastatin)
Advair/ Seretide (fluticasone/ salmeterol)
Plavix (clopidogrel)
Norvasc (amlodipine)
Nexium (esomeprazole)
Enbrel (etanercept)
Remicade (infliximab)
Zyprexa (olanzapine)
Prevacid (lansoprazole)
Diovan/ Co-Diovan/ Provas/ Miten (valsartan/ hydrochlorothiazide)
Blockbuster trends

Blockbusters by drug type
Blockbusters by therapy area
Blockbusters by company

Chapter 5 Key companies
Major pharmaceutical companies

Major company financials
Major company locations
Top 10 pharmaceutical companies

Top 10 company financials
Top 10 company value drivers

Leading pharmaceutical companies

Pfizer
GlaxoSmithKline
Sanofi-Aventis
Roche
AstraZeneca
Novartis
Johnson and Johnson
Merck & Co
Wyeth
Eli Lilly


Chapter 6 Key trends and opportunities
Global market forecasts

The US market
The European market
The Japanese market
Other markets

Key therapy area forecasts

Cardiovascular market
Central nervous system market
Alimentary/ metabolism market
Anti-infectives market
Respiratory market
Oncology market

Key product forecasts

Lipitor (atorvastatin)
Advair/ Seretide (fluticasone/ salmeterol)
Plavix (clopidogrel)
Norvasc (amlodipine)
Nexium (esomeprazole)
Enbrel (etanercept)
Remicade (infliximab)
Zyprexa (olanzapine)
Prevacid (lansoprazole)
Diovan/ Co-Diovan (valsartan/ hydrochlorothiazide)
Key company forecasts

Pfizer
GlaxoSmithKline
Sanofi-Aventis
Roche
AstraZeneca
Novartis
Johnson and Johnson
Merck & Co
Wyeth
Eli Lilly

Appendix
Proprietary data sources

Product Trends Database
Company Trends Database

Top 100 pharmaceutical products
Top 62 pharmaceutical companies



LIST OF FIGURES
Figure 1: Global pharmaceutical market, 1999-2006
Figure 2: Report structure
Figure 3: Global pharmaceutical market share by region, 2006
Figure 4: Global pharmaceutical market by region, 2003-2006
Figure 5: US pharmaceutical market, 2003-2006
Figure 6: US pharmaceutical market share by purchasing channel, 2006
Figure 7: US pharmaceutical market by purchasing channel, 2003-2006
Figure 8: US retail pharmaceutical market, 2003-2006
Figure 9: US retail pharmaceutical market share by therapy area, 2006
Figure 10: US retail pharmaceutical market by therapy area, 2003-2006
Figure 11: Top 10 products by US pharmaceutical sales, 2006
Figure 12: Top 10 companies by US pharmaceutical sales, 2006
Figure 13: Top 10 companies by share of US pharmaceutical sales, 2006
Figure 14: European pharmaceutical market, 2003-2006
Figure 15: European pharmaceutical market share by country, 2006
Figure 16: European top 5 retail pharmaceutical market, 2003-2006
Figure 17: European top 5 retail pharmaceutical market share by country, 2006
Figure 18: European top 5 retail pharmaceutical market by country, 2003-2006
Figure 19: European top 5 retail pharmaceutical market share by therapy area, 2006
Figure 20: European top 5 retail pharmaceutical market by therapy area, 2003-2006
Figure 21: Japanese pharmaceutical market, 2003-2006
Figure 22: Japanese pharmaceutical market share by therapy area, 2006
Figure 23: Japanese pharmaceutical market by therapy area, 2003-2006
Figure 24: Global pharmaceutical market by therapy area, 2006
Figure 25: Top 10 product classes by global pharmaceutical sales, 2006
Figure 26: Global retail pharmaceutical market share by therapy area, 2006
Figure 27: Global retail pharmaceutical market by therapy area, 2003-2006
Figure 28: Cardiovascular retail pharmaceutical market, 2003-2006
Figure 29: Cardiovascular retail pharmaceutical market share by country, 2006
Figure 30: Cardiovascular retail pharmaceutical market by country, 2003-2006
Figure 31: Central nervous system retail pharmaceutical market, 2003-2006
Figure 32: Central nervous system retail pharmaceutical market share by country, 2006
Figure 33: Central nervous system retail pharmaceutical market by country, 2003-2006
Figure 34: Alimentary/ metabolism retail pharmaceutical market, 2003-2006
Figure 35: Alimentary/ metabolism retail pharmaceutical market share by country, 2006
Figure 36: Alimentary/ metabolism retail pharmaceutical market by country, 2003-2006
Figure 37: Respiratory retail pharmaceutical market, 2003-2006
Figure 38: Respiratory retail pharmaceutical market share by country, 2006
Figure 39: Respiratory retail pharmaceutical market by country, 2003-2006
Figure 40: Anti-infectives retail pharmaceutical market, 2003-2006
Figure 41: Anti-infectives retail pharmaceutical market share by country, 2006
Figure 42: Anti-infectives retail pharmaceutical market by country, 2003-2006
Figure 43: Musculo-skeletal retail pharmaceutical market, 2003-2006
Figure 44: Musculo-skeletal retail pharmaceutical market share by country, 2006
Figure 45: Musculo-skeletal retail pharmaceutical market by country, 2003-2006
Figure 46: Cytostatics retail pharmaceutical market, 2003-2006
Figure 47: Cytostatics retail pharmaceutical market share by country, 2006
Figure 48: Cytostatics retail pharmaceutical market by country, 2003-2006
Figure 49: Blockbuster drug sales share by drug type, 2006
Figure 50: Blockbuster drug sales share by lifecycle stage, 2006
Figure 51: Blockbuster drug sales share by therapy area, 2006
Figure 52: Blockbuster drug sales share by company, 2006
Figure 53: Major companies pharmaceutical sales, 2004-2006
Figure 54: Major companies revenue share allocation, 2006
Figure 55: Major companies revenue allocation, 2004-2006
Figure 56: Major companies pharmaceutical sales by location, 2006
Figure 57: Top 10 pharma companies pharmaceutical sales, 2004-2006
Figure 58: Top 10 pharma companies by global pharmaceutical sales, 2006
Figure 59: Top 10 biotechnology companies by global revenues, 2006
Figure 60: Top 10 pharma companies revenue share allocation, 2006
Figure 61: Top 10 pharma companies revenue allocation, 2004-2006
Figure 62: Key value drivers for top 10 pharma companies (income), 2006
Figure 63: Key value drivers for top 10 pharma companies (sales), 2006
Figure 64: Key value drivers for top 10 pharma companies (sales/ R&D), 2006
Figure 65: Pfizer therapy area sales, 2004-2006
Figure 66: GlaxoSmithKline therapy area sales, 2004-2006
Figure 67: Sanofi-Aventis blockbuster therapy area sales, 2004-2006
Figure 68: Roche therapy area sales, 2004-2006
Figure 69: AstraZeneca therapy area sales, 2004-2006
Figure 70: Novartis therapy area sales, 2004-2006
Figure 71: Johnson and Johnson blockbuster therapy area sales, 2004-2006
Figure 72: Merck & Co blockbuster therapy area sales, 2004-2006
Figure 73: Wyeth blockbuster therapy area sales, 2004-2006
Figure 74: Eli Lilly therapy area sales, 2004-2006
Figure 75: Global pharmaceutical market forecast, 2003-2011
Figure 76: Global pharmaceutical market forecast by regions, 2003-2010
Figure 77: Top 10 pharmaceutical drugs by forecast sales, 2011
Figure 78: Lipitor (atorvastatin) forecast sales, 2003-2011
Figure 79: Advair/ Seretide (fluticasone/ salmeterol) forecast sales, 2003-2011
Figure 80: Plavix (clopidogrel) forecast sales, 2003-2011
Figure 81: Norvasc (amlodipine) forecast sales, 2003-2011
Figure 82: Nexium (esomeprazole) forecast sales, 2003-2011
Figure 83: Enbrel (etanercept) forecast sales, 2003-2011
Figure 84: Remicade (infliximab) forecast sales, 2003-2011
Figure 85: Zyprexa (olanzapine) forecast sales, 2003-2011
Figure 86: Prevacid (lansoprazole) forecast sales, 2003-2011
Figure 87: Diovan/ Co-Diovan (valsartan/ hydrochlorothiazide) forecast sales, 2003-2011

LIST OF TABLES
Table 1: Global pharmaceutical market trends by region, 2004-2006
Table 2: US pharmaceutical market trends by purchasing channel, 2004-2006
Table 3: US retail pharmaceutical market trends by therapy area, 2003-2006
Table 4: Top 10 products trends by US pharmaceutical sales, 2004-2006
Table 5: European top 5 retail pharmaceutical market trends by country, 2004-2006
Table 6: European top 5 retail pharmaceutical market trends by therapy area, 2004-2006
Table 7: Japanese pharmaceutical market trends by therapy area, 2004-2006
Table 8: Top 10 product classes trends by global pharmaceutical sales, 2005-2006
Table 9: Global retail pharmaceutical market trends by therapy area, 2004-2006
Table 10: Cardiovascular retail pharmaceutical market trends by country, 2004-2006
Table 11: Cardiovascular blockbuster drug sales, 2004-2006
Table 12: Central nervous system retail pharmaceutical market trends by country, 2004-2006
Table 13: Central nervous system blockbuster drug sales, 2004-2006
Table 14: Alimentary/ metabolism retail pharmaceutical market trends by country, 2004-2006
Table 15: Alimentary/ metabolism blockbuster drug sales, 2004-2006
Table 16: Respiratory retail pharmaceutical market trends by country, 2004-2006
Table 17: Respiratory blockbuster drug sales, 2004-2006
Table 18: Anti-infectives retail pharmaceutical market trends by country, 2004-2006
Table 19: Anti-infectives blockbuster drug sales, 2004-2006
Table 20: Musculo-skeletal retail pharmaceutical market trends by country, 2004-2006
Table 21: Musculo-skeletal blockbuster drug sales, 2004-2006
Table 22: Cytostatics retail pharmaceutical market trends by country, 2004-2006
Table 23: Cytostatics blockbuster drug sales, 2004-2006
Table 24: Top 20 products by global pharmaceutical sales, 2004-2006
Table 25: Lipitor (atorvastatin) profile, 2006
Table 26: Advair/ Seretide (fluticasone/ salmeterol) profile, 2006
Table 27: Plavix (clopidogrel) profile, 2006
Table 28: Norvasc (amlodipine) profile, 2006
Table 29: Nexium (esomeprazole) profile, 2006
Table 30: Enbrel (etanercept) profile, 2006
Table 31: Remicade (infliximab) profile, 2006
Table 32: Zyprexa (olanzapine) profile, 2006
Table 33: Prevacid/ Zoton (lansoprazole) profile, 2006
Table 34: Diovan/ Co-Diovan/ Provas/ Miten (valsartan/ hydrochlorothiazide) profile, 2006
Table 35: Top 10 blockbuster products by global pharmaceutical sales growth, 2004-2006
Table 36: Top 10 blockbuster products by declining global pharmaceutical sales, 2004-2006
Table 37: New blockbuster products, 2004-2006
Table 38: Major companies revenue allocation trends, 2004-2006
Table 39: Top 10 pharma companies by global pharmaceutical sales, 2004-2006
Table 40: Top 10 biotechnology companies by global revenues, 2004-2006
Table 41: Top 10 pharma companies revenue allocation trends, 2004-2006
Table 42: Pfizer profile, 2006
Table 43: Pfizer blockbuster sales, 2004-2006
Table 44: GlaxoSmithKline profile, 2006
Table 45: GlaxoSmithKline blockbuster sales, 2004-2006
Table 46: Sanofi-Aventis profile, 2006
Table 47: Sanofi-Aventis blockbuster sales, 2004-2006
Table 48: Roche profile, 2006
Table 49: Roche blockbuster sales, 2004-2006
Table 50: AstraZeneca profile, 2006
Table 51: AstraZeneca blockbuster sales, 2004-2006
Table 52: Novartis profile, 2006
Table 53: Novartis blockbuster sales, 2004-2006
Table 54: Johnson and Johnson profile, 2006
Table 55: Johnson and Johnson blockbuster sales, 2004-2006
Table 56: Merck & Co profile, 2006
Table 57: Merck & Co blockbuster sales, 2004-2006
Table 58: Wyeth profile, 2006
Table 59: Wyeth blockbuster sales, 2004-2006
Table 60: Eli Lilly profile, 2006
Table 61: Eli Lilly blockbuster sales, 2004-2006
Table 62: Global pharmaceutical market forecast by regions, 2003-2011
Table 63: Global pharmaceutical market forecast by therapy area, 2006-2011
Table 64: Top 10 pharmaceutical drugs forecast, 2003-2011
Table 65: Top 10 pharmaceutical companies forecast, 2006-2011
Table 66: Top 100 products by global pharmaceutical sales, 2004-2006
Table 67: Top 62 companies by global pharmaceutical sales, 2004-2006